Mg. Zuñiga-San Martin, Carlos

2020, Hole, Barnaby, Hemmelgarn, Brenda, Brown, Edwina, Brown, Mark, McCulloch, Mignon I., Zuñiga-San Martin, Carlos, Andreoli, Sharon P., Blake, Peter G., Couchoud, Cécile, Cueto Manzano, Alfonso M., Dreyer, Gavin, García García, Guillermo, Jager, Kitty J., McKnight, Marla, Morton, Rachael L., Murtagh, Fliss E.M., Naicker, Saraladevi, Obrador, Gregorio T., Perl, Jeffrey, Rahman, Muhibur, Shah, Kamal D., Van Biesen, Wim, Walker, Rachael C., Yeates, Karen, Zemchenkov, Alexander, Zhao, Ming-Hui, Davies, Simon J., Caskey, Fergus J.

A key component of treatment for all people with advanced kidney disease is supportive care, which aims to improve quality of life and can be provided alongside therapies intended to prolong life, such as dialysis. This article addresses the key considerations of supportive care as part of integrated end-stage kidney disease care, with particular attention paid to programs in low- and middle-income countries. Supportive care should be an integrated component of care for patients with advanced chronic kidney disease, patients receiving kidney replacement therapy (KRT), and patients receiving non-KRT conservative care. Five themes are identified: improving information on prognosis and support, developing context-specific evidence, establishing appropriate metrics for monitoring care, clearly communicating the role of supportive care, and integrating supportive care into existing health care infrastructures. This report explores some general aspects of these 5 domains, before exploring their consequences in 4 health care situations/settings: in people approaching end-stage kidney disease in high-income countries and in low- and middle-income countries, and in people discontinuing KRT in high-income countries and in low- and middle-income countries.

2020, Swanepoel, Charles R., McCulloch, Mignon I., Abraham, Georgi, Donner, Jo-Ann, Alrukhaimi, Mona N., Blake, Peter G., Bunnag, Sakarn, Claus, Stefaan, Dreyer, Gavin, Ghnaimat, Mohammad A., Ibhais, Fuad M., Liew, Adrian, McKnight, Marla, Yewondwossen Tadesse, Mengistu, Naicker, Saraladevi, Niang, Abdou, Obrador, Gregorio T., Perl, Jeffrey, Harun Ur, Rashid, Tonelli, Marcello, Tungsanga, Kriang, Vachharajani, Tushar, Zakharova, Elena, Zuñiga-San Martin, Carlos, Finkelstein, Fredric O.

Prevention and early detection of kidney diseases in adults and children should be a priority for any government health department. This is particularly pertinent in the low-middle-income countries, mostly in Asia, Africa, Latin America, and the Caribbean, where up to 7 million people die because of lack of end-stage kidney disease treatment. The nephrology workforce (nurses, technicians, and doctors) is limited in these countries and expanding the size and expertise of the workforce is essential to permit expansion of treatment for both chronic kidney disease and end-stage kidney disease. To achieve this will require sustained action and commitment from governments, academic medical centers, local nephrology societies, and the international nephrology community.